Morgan Stanley’s Taiwan Liposome TLC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
– Sell
-100
Closed -$1K – 6855
2019
Q3
$1K Hold
100
– – ﹤0.01% 6596
2019
Q2
$1K Sell
100
-257,350
-100% -$1.44M ﹤0.01% 6600
2019
Q1
$1.5M Buy
257,450
+257,350
+257,350% +$1.59M ﹤0.01% 3828
2018
Q4
$1K Buy
+100
New +$594 ﹤0.01% 6547

Other funds holding TLC

Morgan Stanley's TLC Position: Q4 2019 in Review

Morgan Stanley sold out of Taiwan Liposome (TLC) in Q4 2019, closing a stake of 100 shares — an estimated $1K sold.

Morgan Stanley first reported a position in TLC in Q4 2018 and held it in 4 quarters. The position peaked at $1.5M in Q1 2019. 6 funds tracked by Wall St. Rank hold TLC as of Q4 2019.

  • Morgan Stanley reported no remaining Taiwan Liposome position as of Q4 2019 after selling out during the quarter.
  • Morgan Stanley sold 100 Taiwan Liposome shares in Q4 2019, an estimated $1K.
  • Morgan Stanley first reported a position in Taiwan Liposome in Q4 2018 and held it in 4 quarters.
  • Morgan Stanley's Taiwan Liposome position peaked at $1.5M in Q1 2019.
  • 6 funds tracked by Wall St. Rank held Taiwan Liposome as of Q4 2019.

Based on Morgan Stanley's 13F filing for Q4 2019, filed 14 Feb 2020.